Antitumor agent for thyroid cancer

  • US 9,006,256 B2
  • Filed: 04/08/2011
  • Issued: 04/14/2015
  • Est. Priority Date: 05/18/2006
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating at least one disease selected from the group consisting of multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract, the method comprising the step of administering an effective amount of an RET kinase inhibiting substance to a patient in need thereof, wherein said RET kinase inhibiting substance is4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof.

View all claims

    Thank you for your feedback